BriaCell Therapeutics (BCTX) said Wednesday that a phase 2 study of its Bria-IMT regimen with check point inhibitors to treat metastatic breast cancer showed positive survival results.
The study showed a median survival of 17.3 months in certain patients, surpassing the 14.4 months seen for the antibody-drug conjugate treatment Trodelvy, the company said .
For triple-negative breast cancer, the company said Bria-IMT showed survival comparable to Trodelvy but significantly better than chemotherapy, with a 70% improvement.
The drug developer said it plans to further evaluate the results in an ongoing phase 3 trial focused on overall survival.
BriaCell shares rose 27% in recent premarket trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。